Facebook
TwitterPitocin is a prescription injectable medication containing oxytocin, used to induce or strengthen labor by stimulating uterine contractions. It is administered intravenously and manufactured by Endo USA, Inc. This information was generated using AI and is provided for informational and research purposes only.
Facebook
Twitterhttps://peptiq.io/termshttps://peptiq.io/terms
Aggregated anonymized self-reports from PeptIQ users tracking Oxytocin.
Facebook
Twitterhttps://peptalk.fitness/methodologyhttps://peptalk.fitness/methodology
Aggregated, self-reported Oxytocin doses, side-effect frequencies, and outcomes from pseudonymous PepTalk contributors. Unverified, educational only.
Facebook
Twitterhttps://dataintelo.com/privacy-and-policyhttps://dataintelo.com/privacy-and-policy
The oxytocin market was valued at $1.52 billion in 2025 and is projected to reach $2.54 billion by 2034, growing at 5.8% CAGR.
Facebook
TwitterCC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
Breastfeeding behaviors can significantly change mothers' physiological and psychological states. The hormone oxytocin may mediate breastfeeding and mothers' emotion recognition. This study examined the effects of endogenous oxytocin fluctuation via breastfeeding on emotion recognition in 51 primiparous mothers. Saliva oxytocin was assessed before and after the manipulation (breastfeeding or holding an infant), and emotion recognition tasks were conducted. Among mothers who breastfed daily, mothers with more increased levels of oxytocin after breastfeeding showed greater reduced negative recognition and enhanced positive recognition of adult facial expressions. These oxytocin functions accompanying breastfeeding may support continued nurturing behaviors and also affect the general social cognition of other adults beyond any specific effect on infants.
Facebook
Twitterhttps://www.marketresearchintellect.com/terms-and-conditions/https://www.marketresearchintellect.com/terms-and-conditions/
According to Market Research Intellect, the Injection Oxytocin Market stood at USD 1.28 Billion in 2025 and is forecast to reach USD 2.53 Billion by 2035, progressing at a CAGR of 7.0%.
Facebook
Twitterhttps://www.marketresearchintellect.com/terms-and-conditions/https://www.marketresearchintellect.com/terms-and-conditions/
Oxytocin Market size, share, and trend analysis indicates growth from USD 1.3 Billion in 2025 to USD 2.94 Billion by 2035, at a CAGR of 8.5%
Facebook
TwitterAttribution-NonCommercial-ShareAlike 4.0 (CC BY-NC-SA 4.0)https://creativecommons.org/licenses/by-nc-sa/4.0/
License information was derived automatically
The table includes 257 products with the active ingredient Oxytocin.
Facebook
TwitterAnalyze Oxytocin Injection import export data with detailed shipment records, HS codes, importing countries, top buyers, suppliers, and global trade trends.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
Vasopressin and oxytocin are members of the neurohypophyseal hormone family found in all mammalian species. They are present in high levels in the posterior pituitary. Oxytocin stimulates contraction of uterine smooth muscle, and stimulates milk secretion in response to suckling by inducing contraction of myoepithelial cells in the mammary gland. Clinically, it is used to induce labour and promote lactation.Oxytocin receptors are found in uterine smooth muscle, myoepithelial cells in the mammary gland, and in the pituitary. Activation of phosphoinositide metabolism is effected via a pertussis-toxin-insensitive G-protein, probably of the Gq/G11 class.
Facebook
TwitterOxytocin (OXT) (OT) - BioCentury Target Profiles for the biopharma industry
Facebook
Twitterhttps://www.edqm.eu/https://www.edqm.eu/
CEP certificate for Oxytocin issued by EDQM. Includes certificate number CEP 2002-200 - Rev 05, status Valid, and country Latvia.
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
The neurohormone oxytocin regulates many aspects of physiology primarily by binding to its receptor, the oxytocin receptor. The oxytocin receptor gene (Oxtr) has been shown to have alternative transcripts in the mouse brain which may each have different biological functions or be used in specific contexts. A popular animal model for studying oxytocin-dependent social behaviors is the prairie vole, a biparental and monogamous rodent. Alternative transcriptional capacity of Oxtr in prairie voles is unknown. We used 5′ rapid amplification of cDNA ends to identify alternative Oxtr transcription start sites in prairie vole brain tissue and uterine tissue. We then validated expression of specific transcripts in fetal brains and assessed the impact of exogenous oxytocin administration in utero on offspring brain development. We identified seven distinct Oxtr transcripts, all of which are present in both brain and uterine tissue. We then demonstrated that maternal oxytocin administration alters expression of a specific subset of Oxtr transcripts and that these different transcripts are under unique epigenetic regulation, such that in the perinatal period only one of the alternative transcripts is associated with DNA methylation in the Oxtr promoter. These data establish the existence of multiple Oxtr transcripts in prairie vole brain and uterine tissue and implicate oxytocin in the regulation of alternative transcript expression. These data have significant implications for our understanding of null mutant models in both mice and voles and translation in human birth and behavior.
Facebook
Twitterhttps://www.marketresearchintellect.com/terms-and-conditions/https://www.marketresearchintellect.com/terms-and-conditions/
Insights on the Oxytocin Receptor Antagonists Market reveal a valuation of USD 484 Million in 2025, with projections reaching USD 997 Million by 2035 at a CAGR of 7.5%.
Facebook
TwitterCC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
SPM{T_[237.0]} - contrast 1: EV_plac_self
This collection contains fMRI data from a study in which healthy males received L-DOPA (100 mg + 25 mg carbidopa), intranasal oxytocin (24 IU), or placebo using a double-blind placebo-controlled cross-over design. In each session, participants performed a probabilistic reinforcement learning task with potential rewards for themselves, an anonymous other participant, or no one, during functional magnetic resonance imaging. Computational models of reinforcement learning were used to calculate prediction errors (PEs) and learning rates. Contrasts involve the factors drug (L-DOPA, oxytocin, placebo) and recipient (self, other, no one).
(Note that paper links to https://identifiers.org/neurovault.collection:13141, but this collection was accidentally deleted.)
homo sapiens
fMRI-BOLD
group
Probabilistic Selection Task
T
Facebook
TwitterCC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
SPM{T_[416.0]} - contrast 3: Group x Drug: BDD greater in Oxyt
The present study assessed the effects of intranasal oxytocin on the neural basis of processing emotional faces in patients with body dysmorphic disorder (BDD). Twenty BDD patients and 22 matched healthy control participants participated in a randomized, double-blind placebo-controlled within-subject functional magnetic resonance imaging study. Following acute intranasal OXT (24 IU) or placebo administration, we examined group and OXT related differences in task-based amygdala activation and related functional connectivity in response to an emotional face-matching task of fearful, angry, disgusted, sad, surprised and happy faces.
homo sapiens
T
Facebook
TwitterThe implementation of an institutional oxytocin checklist did not affect expert assessment of the use of oxytocin in labor. Checklist is included within the publication's appendix.
Facebook
Twitter
As per our latest research, the global oxytocin closed-loop infusion controller market size reached USD 466 million in 2025, reflecting robust adoption across healthcare settings worldwide. The market is projected to grow at a CAGR of 9.1% from 2026 to 2034, reaching an estimated USD 1,022 million by 2034. This strong growth trajectory is primarily driven by the rising prevalence of labor complications, increasing focus on maternal safety, and the rapid integration of advanced automation technologies in obstetric care. Historical data from 2019 through 2024 confirms a consistent upward trend, with adoption accelerating as healthcare systems in both developed and developing economies modernize their labor and delivery infrastructure.
One of the primary growth factors for the oxytocin closed-loop infusion controller market is the escalating need for precise and personalized drug administration during childbirth. Oxytocin is a critical hormone used for labor induction and the management of postpartum hemorrhage, but its administration requires careful titration to avoid adverse outcomes such as uterine hyperstimulation and fetal distress. Closed-loop infusion controllers, which automatically adjust oxytocin dosage based on real-time feedback from physiological parameters, significantly reduce the risk of under- or over-dosing. The growing awareness among healthcare professionals about the importance of controlled oxytocin delivery, combined with the rising incidence of high-risk pregnancies, is fueling the adoption of these advanced infusion controllers globally. Moreover, the increasing number of births in both developed and developing regions is amplifying the demand for safe and efficient labor management solutions.
Technological advancement in infusion systems represents another significant driver propelling market growth. The integration of sensor-based technologies, artificial intelligence (AI), and machine learning algorithms has revolutionized the capabilities of oxytocin closed-loop infusion controllers. These innovations enable real-time monitoring and adaptive dosing, enhancing patient safety and clinical outcomes. Similar innovation patterns are visible in adjacent fields such as vasopressor infusion control, where closed-loop automation is redefining hemodynamic management. The trend toward digitalization in healthcare, coupled with the proliferation of smart hospitals and maternity clinics, is fostering the deployment of integrated and connected infusion systems. The adoption of AI-driven controllers is particularly notable, as they offer predictive analytics and decision support, further optimizing oxytocin administration and reducing the burden on clinical staff.
The global market is also witnessing favorable regulatory developments and policy initiatives that support the adoption of advanced maternal health technologies. Governments and healthcare organizations are increasingly prioritizing maternal and neonatal safety, leading to investments in modernizing labor and delivery units. Funding for research and development in obstetric care devices, along with the establishment of stringent safety standards, is facilitating the commercialization and acceptance of oxytocin closed-loop infusion controllers. Furthermore, collaborations between medical device manufacturers, research institutions, and healthcare providers are accelerating innovation and expanding the market reach of these controllers, especially in regions with high maternal mortality rates.
From a regional perspective, North America currently holds the largest share of the oxytocin closed-loop infusion controller market, driven by advanced healthcare infrastructure, high awareness levels, and supportive reimbursement policies. Europe follows closely, with significant adoption in countries such as Germany, the United Kingdom, and France. The Asia Pacific region is poised for the fastest growth, fueled by increasing healthcare investments, rising birth rates, and government initiatives to improve maternal he
Facebook
TwitterAttribution 4.0 (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/
License information was derived automatically
IntroductionRole-play, a key creative process in theatre, is used in therapeutic interventions to improve social skills, emotion regulation, and memory. Although role-play is widely used as a psychotherapeutic technique, its mechanisms of action are not fully understood.MethodsOur study introduces a standardized controlled procedure for promoting role-play in the laboratory based on the portrayal of a fictional persona and examines its effects on anxiety, affect, prosocial attitudes, and salivary oxytocin dynamics in 38 participants.ResultsIn our experiment, role-play significantly increased positive affect and prosocial attitudes and decreased anxiety compared to a control condition. Basal salivary oxytocin levels predicted higher gains in positive affect following role-play, suggesting a specific moderating effect of oxytocin. The fictional persona used in the procedure was rated as very happy by subjects, creating a positive social context for the role-play social interaction.DiscussionsWe propose that the observed moderation effect of oxytocin in our study is specific to the role-play condition due to the capacity of role-play to generate an affective regulatory context based on congruency toward the emotional state of the fictional persona. Our findings indicate that basal oxytocin levels could predict specific outcomes of role-play in therapeutical setting. We discuss several psychological and biological mechanisms that could account for the observed effects of role-play and how oxytocin could act as a substrate for them.
Facebook
TwitterCC0 1.0 Universal Public Domain Dedicationhttps://creativecommons.org/publicdomain/zero/1.0/
License information was derived automatically
Unthresholded map
This collection includes unthresholded maps for all the analyses conducted in the study. Only the conjunction maps are presented thresholded at voxel level p=0.002.
homo sapiens
fMRI-BOLD
group
pleasantness rating task
T
Facebook
TwitterPitocin is a prescription injectable medication containing oxytocin, used to induce or strengthen labor by stimulating uterine contractions. It is administered intravenously and manufactured by Endo USA, Inc. This information was generated using AI and is provided for informational and research purposes only.